The Medicines Company of Parsippany, N.J., has received approval for its IV-administered Cleviprex (clevidipine butyrate) injectable emulsion for reducing BP when oral treatment is neither feasible nor desirable.
SAN FRANCISCO—Heavy consumption of artificially sweetened beverages was associated with almost twice the risk of diabetes in a long-term, community-based prospective study, researchers reported here at the American Diabetes Association annual meeting.
Treatment with angiotensin receptor blockers (ARBs) may reduce the risk of fatal and non-fatal CVD events in hemodialysis patients, according to researchers at the Saitama Medical University in Saitama, Japan.
Age is an independent prognostic factor in women, but not men, with renal cell carcinoma (RCC), according to researchers.
When Florida physician Bernd Wollschlaeger, MD, asked an elderly female CKD patient to tell him all the medications she was taking, she listed four or five.
PARIS—Older women undergoing surgery for stress urinary incontinence (SUI) fare as well as younger women with respect to perioperative results, but they experience worse two-year outcomes, researchers reported here during a poster session at the Fourth International Consultation on Incontinence.
SAN FRANCISCO—Dietary salt supplementation may reduce the antihypertensive effects of the angiotensin receptor blocker (ARB) telmisartan in patients with type 2 diabetes and hypertension, investigators reported at the 68th Scientific Sessions of the American Diabetes Association. The effect is independent of habitual sodium dietary status.
Contrary to original findings from the Prostate Cancer Prevention Trial (PCPT), finasteride does not increase the risk of high-grade prostate cancer, according to a new analysis.
Oral estrogen therapy in post-menopausal women is associated with loss of renal function, according to Canadian researchers.
TORONTO—Transplantation of kidneys from deceased donors aged 70 years or older is associated with a high relative risk of graft loss or death, according to researchers.
